Noninvasive liver fibrosis markers are independently associated with carotid atherosclerosis risk in patients with nonalcoholic fatty liver disease

References

• Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi: 10.1016/S0140-6736(20)32511-3.
   PubMed Web of Science ®Google Scholar
• Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. 2014;20(26):8407–8415. doi: 10.3748/wjg.v20.i26.8407.
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol. 2021;18(2):85–86. doi: 10.1038/s41575-020-00406-0.
   PubMed Web of Science ®Google Scholar
• Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev. 2008;29(7):939–960. doi: 10.1210/er.2008-0009.
   PubMed Web of Science ®Google Scholar
• Sohn W, Kwon HJ, Chang Y, et al. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022;20(5):e1135–e1148. doi: 10.1016/j.cgh.2021.06.042.
   PubMed Web of Science ®Google Scholar
• Song DS, Chang UI, Kang SG, et al. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. Gut Liver. 2019;13(6):658–668. doi: 10.5009/gnl18439.
   PubMed Web of Science ®Google Scholar
• Shao C, Xu L, Lei P, et al. Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease. J Transl Med. 2023;21(1):12. doi: 10.1186/s12967-022-03760-6.
   PubMed Web of Science ®Google Scholar
• Cleveland ER, Ning H, Vos MB, et al. Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. J Gen Intern Med. 2019;34(12):2772–2778. doi: 10.1007/s11606-019-05340-9.
   PubMed Web of Science ®Google Scholar
• Rundek T, Gardener H, Della-Morte D, et al. The relationship between carotid intima-media thickness and carotid plaque in the Northern Manhattan Study. Atherosclerosis. 2015;241(2):364–370. doi: 10.1016/j.atherosclerosis.2015.05.027.
   PubMed Web of Science ®Google Scholar
• Shimoda S, Kitamura A, Imano H, et al. Associations of carotid intima-media thickness and plaque heterogeneity with the risks of stroke subtypes and coronary artery disease in the japanese general population: the circulatory risk in communities study. J Am Heart Assoc. 2020;9(19):e017020. doi: 10.1161/JAHA.120.017020.
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15(10):1604–1611.e1. doi: 10.1016/j.cgh.2017.04.045.
   PubMed Web of Science ®Google Scholar
• Jamalinia M, Zare F, Lankarani KB. Systematic review and meta-analysis: association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023;58(4):384–394. doi: 10.1111/apt.17617.
   PubMed Web of Science ®Google Scholar
• Naimi RM, Hvistendahl M, Nerup N, et al. Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2 trial. EBioMedicine. 2019;46:444–451. doi: 10.1016/j.ebiom.2019.07.016.
   PubMed Web of Science ®Google Scholar
• Pirmoazen AM, Khurana A, El Kaffas A, et al. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics. 2020;10(9):4277–4289. doi: 10.7150/thno.40249.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17(9):1877–1885.e1875. doi: 10.1016/j.cgh.2018.12.031.
   PubMed Web of Science ®Google Scholar
• Ballestri S, Mantovani A, Di Girolamo M, et al. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage. 2023;3(1):1. doi: 10.20517/mtod.2022.23.
   Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi: 10.1002/hep.29367.
   PubMed Web of Science ®Google Scholar
• Bril F, Ortiz-Lopez C, Lomonaco R, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35(9):2139–2146. doi: 10.1111/liv.12840.
   PubMed Web of Science ®Google Scholar
• Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93. doi: 10.1016/j.echo.2007.11.011.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi: 10.1002/hep.21178.
   PubMed Web of Science ®Google Scholar
• Wang HW, Peng CY, Lai HC, et al. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. Sci Rep. 2017;7(1):3259. doi: 10.1038/s41598-017-03589-w.
   PubMedGoogle Scholar
• Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi: 10.1053/jhep.2003.50346.
   PubMed Web of Science ®Google Scholar
• Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988;95(3):734–739. doi: 10.1016/s0016-5085(88)80022-2.
   PubMed Web of Science ®Google Scholar
• Tseng PL, Wang JH, Hung CH, et al. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Kaohsiung J Med Sci. 2013;29(7):385–395. doi: 10.1016/j.kjms.2012.11.007.
   PubMed Web of Science ®Google Scholar
• Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986–992. doi: 10.1053/jhep.2002.36128.
   PubMed Web of Science ®Google Scholar
• Xanthakos SA, Jenkins TM, Kleiner DE, et al. High prevalence of nonalcoholic fatty liver disease in adolescents undergoing bariatric surgery. Gastroenterology. 2015;149(3):623–634.e628. doi: 10.1053/j.gastro.2015.05.039.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49(4):600–607. doi: 10.1016/j.jhep.2008.06.012.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Behling C, Angeles JE, et al. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology. 2017;66(5):1474–1485. doi: 10.1002/hep.29241.
   PubMed Web of Science ®Google Scholar
• Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241. doi: 10.1038/35025203.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565. doi: 10.1002/hep.29085.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.e10. doi: 10.1053/j.gastro.2015.04.043.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–1625.e1612. doi: 10.1053/j.gastro.2020.01.043.
   PubMed Web of Science ®Google Scholar
• Brouha SS, Nguyen P, Bettencourt R, et al. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: a prospective study. Eur Radiol. 2018;28(4):1345–1355. doi: 10.1007/s00330-017-5075-6.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57(4):1357–1365. doi: 10.1002/hep.26156.
   PubMed Web of Science ®Google Scholar
• Hagström H, Nasr P, Ekstedt M, et al. Cardiovascular risk factors in non-alcoholic fatty liver disease. Liver Int. 2019;39(1):197–204. doi: 10.1111/liv.13973.
   PubMed Web of Science ®Google Scholar
• Lauridsen BK, Stender S, Kristensen TS, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J. 2018;39(5):385–393. doi: 10.1093/eurheartj/ehx662.
   PubMed Web of Science ®Google Scholar
• Martínez-Arranz I, Bruzzone C, Noureddin M, et al. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology. 2022;76(4):1121–1134. doi: 10.1002/hep.32427.
   PubMed Web of Science ®Google Scholar
• Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121(1):72–78. doi: 10.1016/j.amjmed.2007.08.041.
   PubMed Web of Science ®Google Scholar
• Shabbirhussain BV, Singh S, Dixit VK, et al. Carotid intima media as predictor of liver fibrosis in type 2 diabetes mellitus with NAFLD. Diabetes Metab Syndr. 2022;16(7):102560. doi: 10.1016/j.dsx.2022.102560.
   PubMedGoogle Scholar
• Bhatia L, Scorletti E, Curzen N, et al. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. Atherosclerosis. 2016;246:13–20. doi: 10.1016/j.atherosclerosis.2015.12.028.
   PubMed Web of Science ®Google Scholar
• Sinn DH, Cho SJ, Gu S, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology. 2016;151(3):481–488.e481. doi: 10.1053/j.gastro.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi: 10.1016/j.jhep.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu M, Wang T, et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis. 2015;241(1):145–150. doi: 10.1016/j.atherosclerosis.2015.05.002.
   PubMed Web of Science ®Google Scholar
• Arai T, Atsukawa M, Tsubota A, et al. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep. 2021;11(1):15938. doi: 10.1038/s41598-021-95581-8.
   PubMed Web of Science ®Google Scholar
• Ojima S, Kubozono T, Kawasoe S, et al. Fib4 index is a more relevant marker for pulse wave velocity but not for carotid intima-media thickness in a men population. Eur Heart J. 2020;41(Supplement_2):ehaa946.2896. doi: 10.1093/ehjci/ehaa946.2896.
   Google Scholar
• Guo YC, Zhou Y, Gao X, et al. Association between nonalcoholic fatty liver disease and carotid artery disease in a community-based Chinese population: a cross-sectional study. Chin Med J (Engl). 2018;131(19):2269–2276. doi: 10.4103/0366-6999.241797.
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. Metabolism. 2021;121:154752. doi: 10.1016/j.metabol.2021.154752.
   PubMed Web of Science ®Google Scholar
• Shao C, Ye J, Li F, et al. Early predictors of cardiovascular disease risk in nonalcoholic fatty liver disease: non-obese versus obese patients. Dig Dis Sci. 2020;65(6):1850–1860. doi: 10.1007/s10620-019-05926-7.
   PubMed Web of Science ®Google Scholar
• Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110(7):921–937. doi: 10.1007/s00392-020-01709-7.
   PubMed Web of Science ®Google Scholar
• Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014;20(25):8082–8091. doi: 10.3748/wjg.v20.i25.8082.
   PubMed Web of Science ®Google Scholar
• Podszun MC, Alawad AS, Lingala S, et al. Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biol. 2020;37:101710. doi: 10.1016/j.redox.2020.101710.
   PubMed Web of Science ®Google Scholar
• Hargrove L, Kennedy L, Demieville J, et al. Bile duct ligation-induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cell-deficient KitW-sh mice. Hepatology. 2017;65(6):1991–2004. doi: 10.1002/hep.29079.
   PubMed Web of Science ®Google Scholar
• Hall KC, Bernier SG, Jacobson S, et al. sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH. Proc Natl Acad Sci U S A. 2019;116(22):11057–11062. doi: 10.1073/pnas.1821045116.
   PubMed Web of Science ®Google Scholar
• Dikalov SI, Dikalova AE. Crosstalk between mitochondrial hyperacetylation and oxidative stress in vascular dysfunction and hypertension. Antioxid Redox Signal. 2019;31(10):710–721. doi: 10.1089/ars.2018.7632.
   PubMed Web of Science ®Google Scholar
• Saiki P, Yoshihara M, Kawano Y, et al. Anti-inflammatory effects of heliangin from jerusalem artichoke (helianthus tuberosus) leaves might prevent atherosclerosis. Biomolecules. 2022;12(1):91. doi: 10.3390/biom12010091.
   PubMed Web of Science ®Google Scholar
• Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118(3):984–993. doi: 10.1172/JCI32970.
   PubMed Web of Science ®Google Scholar
• Nussberger J, Aubert J-F, Bouzourene K, et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51(5):1306–1311. doi: 10.1161/HYPERTENSIONAHA.108.110932.
   PubMed Web of Science ®Google Scholar
• Ramadan R, Dhawan SS, Binongo JNG, et al. Effect of angiotensin II type I receptor blockade with valsartan on carotid artery atherosclerosis: a double blind randomized clinical trial comparing valsartan and placebo (EFFERVESCENT). Am Heart J. 2016;174:68–79. doi: 10.1016/j.ahj.2015.12.021.
   PubMed Web of Science ®Google Scholar
• Chen G, Yang JC, Zhang GX, et al. Evaluation of six noninvasive methods for the detection of fibrosis in chinese patients with obesity and nonalcoholic fatty liver disease. Obes Surg. 2022;32(11):3619–3626. doi: 10.1007/s11695-022-06251-1.
   PubMed Web of Science ®Google Scholar
• Sigrist RMS, Liau J, Kaffas AE, et al. Ultrasound elastography: review of techniques and clinical applications. Theranostics. 2017;7(5):1303–1329. doi: 10.7150/thno.18650.
   PubMed Web of Science ®Google Scholar
• Lv T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol. 2019;34(10):1676–1684. doi: 10.1111/jgh.14746.
   PubMed Web of Science ®Google Scholar
• Sandahl TD, Laursen TL, Munk DE, et al. The prevalence of Wilson’s disease: an update. Hepatology. 2020;71(2):722–732. doi: 10.1002/hep.30911.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Zhou Y, Hu YQ, et al. Epidemiological characteristics and prevention strategies of viral hepatitis in Chongwen District of Beijing during 1997-2006. Zhonghua Yu Fang Yi Xue Za Zhi. 2008;42(8):592–595. doi: 10.3321/j.issn:0253-9624.2008.08.012.
   PubMedGoogle Scholar